In developed countries 1-2% of the population will experience a chronic wound during their lifetime. Often disguised as a comorbid condition, chronic wounds represent a silent epidemic that affects a large fraction of the world population.
The expected global value of the chronic wound care market by 2027 is 16,36 billion USD. Increasing costs of health care, an aging population, recognition of difficult-to-treat infection threats such as biofilms, and the continued threat of diabetes and obesity worldwide make chronic wounds a substantial clinical, social, and economic challenge.
A biofilm is present in 78% of all wounds. This is a thin layer of glycoproteic material from actively replicating bacteria that adheres to the lesion and results in recurring infections, preventing the wound from healing.
Chronic wounds: The silent epidemic
Globally millions of people suffer from chronic wounds, with devastating consequences for patients and billions of healthcare costs for society. Patients with chronic wounds experience severe pain and distress, reduced mobility and a sense of isolation, while for society health care costs rise due to an increasing number of patients and a lack of effective solutions.
Most wounds become chronic as long as an infection inside the wound bed prevents the natural healing process. Current methods fail to effectively battle these infections and therefore mainly focus on reducing patients’ discomfort rather than healing the wound.
These methods require an approach in which different treatments must be applied simultaneously before being effective. This results in high costs and a time-consuming process, without an actual perspective for the patient.
DEBx Medical is on track to deliver better and less inconvenient chronic wound treatments globally. Our first product, DEBRICHEM, removes the infection in a chronic wound in just 60 seconds, thereby putting ourselves in the market as a leading company in this area.
We do not only want to become the leading company, once we obtain that goal, we also propose to keep that leading position. We therefore continuously anticipate on new research and developments and are currently working hard to expand our product line to supply different products for every phase in wound care. Ranging from diagnosis and treatment of the infection in chronic wounds to aftercare and the maintenance of a healthy wound bed.